Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04271202 · ClinicalTrials.gov registry record · Phase 4
Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action
A Phase 4 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT04271202 is a Phase 4 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 64 participants.
The verdict
NCT04271202, a Phase 4 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to understand better the mechanisms of action of calcitonin gene related peptide (CGRP) targeted monoclonal antibodies in migraine prevention. Specifically, the protocol will allow the investigators to determine whether the main site of action of this novel and recently-approved class of migraine prophylactic drugs act inside or outside the brain and if so, where.
Interventions
- DRUG Emgality 120 MG in 1 ML Prefilled Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2023-11-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04271202
The ClinicalTrials.gov registry entry for NCT04271202 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Emgality 120 MG in 1 ML Prefilled Syringe is the first listed.
NCT04271202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04271202 about?
NCT04271202 is a clinical study titled "Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action". The purpose of this study is to understand better the mechanisms of action of calcitonin gene related peptide (CGRP) targeted monoclonal antibodies in migraine prevention. Specifically, the protocol will allow the investigators to determine whether the main site of action of this novel and recently-...
What is the current status of trial NCT04271202?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2020-07-29. Estimated completion is 2023-11-22.
What interventions are being tested in trial NCT04271202?
The interventions under investigation include: Emgality 120 MG in 1 ML Prefilled Syringe (DRUG).
Who is sponsoring clinical trial NCT04271202?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.